▷ A hyper-compact CRISPR technology developed by GenKOre is considered a potential …


25.10.2021 – 04:25

GenKOre

DAEJEON, South Korea, Feb. 7 / PRNewswire /

On September 2, 2021, a scientific paper by GenKOre on the new hyper-compact CRISPR system called CRISPR / Cas12f-GE was published in an online edition of Nature Biotechnology (IF 54.9), one of the world’s leading biotechnology journals.

For gene therapy to be effective, it is imperative that the genetic payload is delivered to the desired location in the patient’s body. The best way to achieve this is to use the adeno-associated virus (AAV) as a vector. AAV is an unenveloped single-stranded DNA virus that invades cells that are either dividing or not dividing. AAV only reproduces when a helper virus is present and is therefore not pathogenic to humans. Because of these properties, AAV is an effective and practical method of introducing genes into various cell types and is used as a vector in gene therapy. With CRISPR / Cas9 technology, however, the size of the scissor gene is very large and it is difficult to transport the gene into the human body using a virus carrier (AAV). For this reason, the clinical application of CRISPR / Cas9 as gene therapy is very limited.

Since the size of the gene in the “CRISPR / Cas12f-GE” system developed by GenKOre is only one third the size of Cas9, it is an ideal payload for AAV transmission. GenKOre has proven its potential benefit as the best gene therapy by improving editing efficiency. In addition to the high editing efficiency, it has proven to be effective and safe gene scissors when it comes to the off-target problem, a chronic weakness of the CRISPR gene scissors.

The Cas12f-GE hypercompact CRISPR system has shown its value as a therapeutic agent that can be used extensively in the development of medical treatments for patients suffering from chronic lifelong illnesses because of the lack of basic cures.

GenKOre, which successfully developed this new technology, is a spin-off company from the Korea Research Institute of Bioscience & Biotechnology (KRIBB), a research institute funded by the South Korean government.

Dr. Yong-Sam Kim, CEO of GenKOre, said, “I hope our research results will start a revolution in gene therapy with this genome editing tool. Our technology can be considered a breakthrough as it is the main obstacle to the original Eliminates CRISPR technology and I am optimistic that our technology, when combined with existing gene scissors, will contribute to people’s health and well-being. “

With the successful development of CRISPR / Cas12f-GE, GenKOre plans to step up gene therapy and new product development through its unique gene scissors technology and partner with other companies to become a leader in gene therapy and new plant biotechnology.

For more information on the GenKOre study published online by Nature Biotechnology, visit https://www.nature.com/articles/s41587-021-01009-z.

The GenKOre website is www.genkore.com

Photo – https://mma.prnewswire.com/media/1665213/gene_scissor_technology.jpg

Photo – https://mma.prnewswire.com/media/1665214/GenKOre.jpg

Press contact:

Gabriel Im
+82-70-8680-2731
[email protected]

Original content by: GenKOre, transmitted by news aktuell


www.presseportal.de

Leave a Reply

Your email address will not be published. Required fields are marked *